Sorafenib in combination with trans-arterial chemoembolization for advanced hepatocellular carcinoma: a retrospective Study at three German Liver centers

被引：0
|
作者：
Goeller, M. [1 ]
Fischer, K. [2 ]
den Winkel, P. Op [2 ]
den Winkel, M. Op [2 ]
Schott, E. [3 ]
Welker, M. [1 ]
Zangos, S.
Vogl, T. [4 ]
Bechstein, W. [5 ]
Zeuzem, S. [1 ]
Kolligs, F. [2 ]
Trojan, J. [1 ]
机构：
[1] Univ Frankfurt Klinikum, Med Klin 1, Frankfurt, Germany
[2] Klinikum Univ Munchen, Med Klin 2, Munich, Germany
[3] Charite, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany
[4] Goethe Univ Frankfurt, Inst Diagnost & Intervent Radiol, D-60054 Frankfurt, Germany
[5] Univ Frankfurt Klinikum, Klin Allgemein & Visceralchirurg, Frankfurt, Germany
来源：
INTERNIST | 2013年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [31] Bilio-pleural fistula following trans-arterial chemoembolization in a patient with hepatocellular carcinoma
    Lewis, Jeffrey
    Gehlbach, Brian
    Aytekin, Oto
    Chennat, Jennifer
    Mohanty, Smruti
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S217 - S217
  • [32] Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma
    Park, Yehyun
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Yeon, Jong Eun
    Byun, Kwan Soo
    Kim, Hye Soo
    Kim, Ji Hoon
    Kim, Seung Up
    BMC CANCER, 2019, 19 (1)
  • [33] Understanding surrogate measures of overall survival after trans-arterial chemoembolization of hepatocellular carcinoma
    Cucchetti, Alessandro
    Casadei Gardini, Andrea
    LIVER INTERNATIONAL, 2021, 41 (05) : 891 - 893
  • [34] Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature
    O. Abdel-Rahman
    Z. A. Elsayed
    Digestive Diseases and Sciences, 2013, 58 : 3389 - 3396
  • [35] Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature
    Abdel-Rahman, O.
    Elsayed, Z. A.
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (12) : 3389 - 3396
  • [36] Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma as a Bridge to Liver Transplantation: A Retrospective Study
    Bouchard-Fortier, Antoine
    Lapointe, Real
    Perreault, Pierre
    Bouchard, Louis
    Pomier-Layrargues, Gilles
    INTERNATIONAL JOURNAL OF HEPATOLOGY, 2011, 2011
  • [37] Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma
    Huang, Yao-Kuang
    Yen, Chieh-Ling
    Shiu, Sz-Iuan
    Lee, Shou-Wu
    Chang, Pi-Yi
    Yeh, Hong-Zen
    Lee, Teng-Yu
    PLOS ONE, 2017, 12 (11):
  • [38] Trans-arterial chemoembolization as a viable alternative to radiofrequency ablation: a study on early to intermediate hepatocellular carcinoma in an Asian population
    Dan, Yock Young
    Lim, Jia Chen
    Chong, Chern Hao
    Kow, Alfred
    Ganpathi, Shridar
    Chang, Stephen
    Da Costa, Maureen
    Madhavan, Krishnakumar
    Lim, Seng Gee
    Tay, Wei Rong Benjamin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 20 - 20
  • [39] Hepatocellular carcinoma in cirrhotic patients waiting for liver transplantation: Radio-frequency ablation versus trans-arterial chemoembolization
    Nseir, Hannan
    Shapiro, Taryn
    Elias, Georg
    Pahari, Mohan
    Shankar, Sridhar
    Ducksoo, Kim
    Brown, Melissa
    Anwar, Nadeem
    Rastallini, Cristiana
    Cicalese, Luca
    TRANSPLANT INTERNATIONAL, 2007, 20 : 4 - 4
  • [40] Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
    Takamasa Ohki
    Koki Sato
    Mari Yamagami
    Daisaku Ito
    Tomoharu Yamada
    Koki Kawanishi
    Kentaro Kojima
    Michiharu Seki
    Nobuo Toda
    Kazumi Tagawa
    Clinical Drug Investigation, 2015, 35 : 751 - 759
12345